LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)

PMPA（替诺福韦）的长期安全性和有效性

• 批准号: 7562141
• 负责人: KOEN K VAN ROMPAY
• 金额: $ 18.16万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562141
• 关键词: Acquired Immunodeficiency Syndrome; Adenine; Animal Model; Antiviral Agents; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV Infections; Human; Institution; Macaca; Newborn Infant; Research; Research Personnel; Resources; SIV; Safety; Source; Tenofovir; Therapeutic; Toxic effect; United States National Institutes of Health; Virus Diseases; novel; pinacolyl methylphosphonic acid

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: The objective of this project is to find better and safer antiviral drugs to treat HIV infection. Simian immunodeficiency virus infection of newborn and infant macaques is a useful animal model of human AIDS to evaluate novel antiviral drugs. Previously, we initiated studies to evaluate the long-term therapeutic and toxic effects of tenofovir (9-[2-(phosphonomethoxy)-propyl]adenine; PMPA).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 目的：该项目的目的是找到更好，更安全的抗病毒药物来治疗HIV感染。新生儿和婴儿猕猴的猿猴免疫缺陷病毒感染是评估新型抗病毒药物的有用动物模型。以前，我们启动了研究，以评估替诺福韦（9- [2-（磷酸氧基） - 丙烷]腺嘌呤； PMPA）的长期治疗和毒性作用。